UNSPSC 51334315: Zuclopenthixol acetate

This classification denotes the acetate form of an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47ISU063SG. European Medicines Agency schedules Zuclopenthixol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00195MIG. Zuclopenthixol generally arises in the molecular formula C22H25CLN2OS.

UNSPSC 51334315 Zuclopenthixol acetate is a Commodity code nominally identifying a specific atypical antipsychotic pharmaceutical, but recent state and local procurement activity under this code shows little direct alignment with the code's product scope. The opportunities tagged to this code reflect broader pharmaceutical and drug-management procurement: naloxone and drug deactivation systems for community health emergency response, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing channels. State and local issuing bodies soliciting pharmaceutical products and drug management solutions include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participating states). The mix spans individual county health procurement, state-level pharmacy benefit program design, and multi-jurisdictional cooperative contracting vehicles.

Recent activity appears concentrated in Florida, Texas, and Minnesota. Seminole County issued IFB 60459723LAS on June 30, 2026, closing July 26, 2023 (note: date discrepancy in source), to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, structured as exploratory market intelligence rather than a binding competitive award. The Minnesota Department of Administration issued RFP S1070000015802 on January 20, 2026, closing March 26, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) for distribution across participating state and local facilities, with evaluation weighted 75 percent on price competitiveness and 25 percent on administrative compliance and capability factors. None of these opportunities directly involve zuclopenthixol acetate or atypical antipsychotic procurement specifically.